|

Rezvilutamide Clinical Trials

6 actively recruiting trials

Also known as: ADT, SHR3680

Pipeline

Phase 2: 5Phase 3: 1

Top Sponsors

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School3
  • The First Affiliated Hospital with Nanjing Medical University1
  • The First Affiliated Hospital of Xiamen University1
  • Peking University First Hospital1

Indications

  • Cancer6
  • Biochemical Recurrence2
  • Locally Advanced Prostate Cancer2
  • Prostate Cancer2
  • Salivary Gland Neoplasm Duct1

Other6 trials

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
Phase 2
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
Phase 3
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
Phase 2
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Phase 2
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Phase 2
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.